Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report
Abstract
Keywords
Kaynakça
- 1. Zeka AN, Taşbakan M, Pullukçu H, et al. Evaluation of zygomycosis cases by pooled analysis method reported from Turkey. Mikrobiyol Bul 2013;47:708-716.
- 2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-653.
- 3. Aslan M, Öz Y, Akay MO, Akşit F. Evaluation of febrile neutropenia in hematologic malignancy patients. Mediterr J Infect Microb Antimicrob 2014; 3:20.
- 4. Özden M, Denk A, Demirdağ K, Elkıran T. Investigation of Febrile Neutropenic Cases and Risk Factors. Mediterr J Infect Microb Antimicrob 2014;2:3.
- 5. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis 2013. Clin Microbiol Infec 2014; 20 Suppl. 3:5-26.
- 6. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007;117: 2649-2657.
- 7. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012;67:715-722.
- 8. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001; 125: 375-378.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Sağlık Kurumları Yönetimi
Bölüm
Olgu Sunumu
Yazarlar
Uğur Önal
Bu kişi benim
Yayımlanma Tarihi
1 Mart 2016
Gönderilme Tarihi
16 Temmuz 2017
Kabul Tarihi
6 Ağustos 2015
Yayımlandığı Sayı
Yıl 2016 Cilt: 6 Sayı: 1